Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) advancing by 0.3%.
BridgeBio Pharma (BBIO) stock was up 3.8% after the company said it has met the primary endpoint in a late-stage trial of the oral drug infigratinib, for the treatment of children living with achondroplasia, or bone dwarfism.
Viridian Therapeutics (VRDN) shares were up more than 8% after the company said Lumvoa received approval from the US Food and Drug Administration to treat thyroid eye disease, an autoimmune disease.
Zymeworks (ZYME) has signed a definitive agreement to acquire Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 5% and Theravance Biopharma stock fell 3.5% pre-bell.